UK-based Vernalis and French pharmaceutical company Servier have entered a new oncology drug discovery collaboration.

Under the latest two-year agreement, Vernalis' fragment-based and structure-based drug discovery platform will be combined with the oncology expertise at Servier.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Since 2007, the two companies have entered several partnership agreements. The previous collaboration included discovery of products targeting Bcl-2 and Mcl-1 that are currently in clinical development.

Bcl-2 derives its name from B-cell lymphoma 2 and is an anti-apoptotic protein that plays a role in many blood cancers, while Mcl-1 is a myeloid cell leukaemia protein of the Bcl-2 family of proteins.

"This new collaboration further validates our fragment-based drug discovery platform and the strength and success of our relationship with Servier."

Vernalis CEO Ian Garland said: "This new collaboration further validates our fragment-based drug discovery platform and the strength and success of our relationship with Servier.

See Also:

“We look forward to working together to develop exciting new cancer treatment opportunities to add to the already disclosed success in targeting Bcl-2 and Mcl-1."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the new partnership, Vernalis is set to receive an upfront payment of €2m, fees, research milestones and a share in the downstream success of any products as a result of this collaboration.

Vernalis has currently three approved products: Tuzistra XR targeting the US prescription cough-cold market, Moxatag, a once-daily formulation of the antibiotic, amoxicillin, and frovatriptan for the acute treatment of migraine.

Servier is also developing a portfolio of new cancer treatments with partners worldwide.